JP2023533162A - 哺乳動物における疾患の予防及び／又は治療に有用な組成物及び方法 - Google Patents

哺乳動物における疾患の予防及び／又は治療に有用な組成物及び方法 Download PDF

Info

Publication number
JP2023533162A
JP2023533162A JP2022575231A JP2022575231A JP2023533162A JP 2023533162 A JP2023533162 A JP 2023533162A JP 2022575231 A JP2022575231 A JP 2022575231A JP 2022575231 A JP2022575231 A JP 2022575231A JP 2023533162 A JP2023533162 A JP 2023533162A
Authority
JP
Japan
Prior art keywords
ksp37
protein
viral
subject
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533162A5 (https=
Inventor
オルガ パトリシア ジエステイラ ダ シルバ スミット，ミシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viro Gen Pty Ltd
Original Assignee
Viro Gen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viro Gen Pty Ltd filed Critical Viro Gen Pty Ltd
Publication of JP2023533162A publication Critical patent/JP2023533162A/ja
Publication of JP2023533162A5 publication Critical patent/JP2023533162A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022575231A 2020-07-09 2021-07-09 哺乳動物における疾患の予防及び／又は治療に有用な組成物及び方法 Pending JP2023533162A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ZA2020/04008 2020-07-09
ZA2020/03850 2020-07-09
ZA202003850 2020-07-09
ZA202004008 2020-07-09
PCT/IB2021/056179 WO2022009165A1 (en) 2020-07-09 2021-07-09 Compositions and methods useful for the prevention and/or treatment of disease in mammals

Publications (2)

Publication Number Publication Date
JP2023533162A true JP2023533162A (ja) 2023-08-02
JP2023533162A5 JP2023533162A5 (https=) 2024-01-19

Family

ID=79552952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575231A Pending JP2023533162A (ja) 2020-07-09 2021-07-09 哺乳動物における疾患の予防及び／又は治療に有用な組成物及び方法

Country Status (16)

Country Link
US (1) US20240091310A1 (https=)
EP (1) EP4178604A4 (https=)
JP (1) JP2023533162A (https=)
KR (1) KR20230038230A (https=)
CN (1) CN115720520A (https=)
AU (1) AU2021304479A1 (https=)
BR (1) BR112022026874A2 (https=)
CA (1) CA3179965A1 (https=)
CL (1) CL2023000073A1 (https=)
CO (1) CO2022019251A2 (https=)
IL (1) IL299661A (https=)
MX (1) MX2023000113A (https=)
PE (1) PE20231554A1 (https=)
PH (1) PH12023550038A1 (https=)
WO (1) WO2022009165A1 (https=)
ZA (1) ZA202213371B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025215561A1 (en) * 2024-04-09 2025-10-16 Viro-Gen (Pty) Ltd Plasmid for expression of ksp37
WO2025221871A1 (en) * 2024-04-16 2025-10-23 The Trustees Of Columbia University In The City Of New York Expansion, propagation, and modulation of immune cell subsets by peptides
WO2025233868A1 (en) * 2024-05-07 2025-11-13 Viro-Gen (Pty) Ltd Compounds, compositions and methods for treating, reversing or preventing cancer
WO2025233869A1 (en) * 2024-05-07 2025-11-13 Viro-Gen (Pty) Ltd Compounds, compositions and methods for treating, reversing or preventing type 2 diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 9, no. 3, JPN6025030784, 2013, pages 515 - 525, ISSN: 0005822150 *

Also Published As

Publication number Publication date
EP4178604A4 (en) 2024-07-31
PH12023550038A1 (en) 2024-03-11
KR20230038230A (ko) 2023-03-17
WO2022009165A1 (en) 2022-01-13
IL299661A (en) 2023-03-01
BR112022026874A2 (pt) 2023-01-24
CA3179965A1 (en) 2022-01-13
AU2021304479A1 (en) 2023-01-19
PE20231554A1 (es) 2023-10-03
MX2023000113A (es) 2023-03-16
EP4178604A1 (en) 2023-05-17
ZA202213371B (en) 2023-11-29
CO2022019251A2 (es) 2023-03-27
CN115720520A (zh) 2023-02-28
US20240091310A1 (en) 2024-03-21
CL2023000073A1 (es) 2023-07-07

Similar Documents

Publication Publication Date Title
US11090379B2 (en) HIV pre-immunization and immunotherapy
JP2023533162A (ja) 哺乳動物における疾患の予防及び／又は治療に有用な組成物及び方法
JP7260170B2 (ja) 事前の免疫化ステップのないｈｉｖ免疫療法
JP7153332B2 (ja) Ｈｉｖワクチン接種および免疫療法
JP2019517503A (ja) 遺伝子編集戦略によるｈｉｖ−１のネガティブフィードバック調節
CN110770338A (zh) 由人γ-δ T细胞激活肿瘤细胞毒性的方法和组合物
JP2018524335A (ja) Ｈｉｖ予備免疫化および免疫療法
WO2021178571A1 (en) On demand expression of exogenous factors in lymphocytes to treat hiv
EP3768301A1 (en) Compositions and methods of fas inhibition
WO2019169216A1 (en) Exosome targeting of cd4+ expressing cells
US20250302939A1 (en) Vaccine for human t-lymphotropic virus-1
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
JPWO2022244801A5 (https=)
US20080234215A1 (en) DNA composition and uses thereof
OA21071A (en) Compositions and methods useful for the prevention and/or treatment of disease in mammals.
Balog et al. Nef: a pleiotropic modulator of primate lentivirus infectivity and pathogenesis
WO2025064901A2 (en) Hiv vaccination and immunotherapy
JP2004041103A (ja) Ａｉｄｓ治療薬のスクリーニング方法
JP2004089053A (ja) Ａｉｄｓ治療薬のスクリーニング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A917 Reason for reinstatement of right to file examination request

Free format text: JAPANESE INTERMEDIATE CODE: A917

Effective date: 20240801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324